IPM Take
Treatment-resistant schizophrenia is where psychiatry’s pharmacological confidence starts to run out.
A new double-blind sham-controlled trial found that five days of twice-daily fronto-temporal transcranial direct current stimulation produced significantly greater reductions in schizophrenia symptoms than sham treatment. That makes the study worth attention. It does not make tDCS ready for routine care.
The trial was small, short and single-centre. Its value lies in demonstrating a signal strong enough to justify a much harder test.
Executive Summary
The trial randomised 45 inpatients with treatment-resistant schizophrenia, with 39 completing treatment: 20 receiving active tDCS and 19 receiving sham stimulation.
Active stimulation was delivered twice daily for five consecutive days. Participants receiving active treatment had significantly greater reductions in total PANSS scores and symptom domains than participants receiving sham treatment. Quality-of-life improvements were observed but did not remain statistically significant after correction.
The study included no meaningful long-term follow-up, meaning durability is unknown. Its small single-site inpatient sample also limits generalisability.
Why it matters
- Treatment-resistant schizophrenia carries enormous clinical and social burden. Patients may continue experiencing psychosis and negative symptoms despite multiple antipsychotic trials, while clozapine remains underused and difficult to manage in many systems.
- A low-cost, non-invasive adjunct such as tDCS could become important if larger trials reproduce the result. The barrier is not the attractiveness of the technology; it is proving that a dramatic five-day signal persists outside a small research setting.
Psychiatry has spent decades improving antipsychotic medication while leaving a substantial group of patients behind.
Treatment resistance is not a small residual category. It means persistent hallucinations, delusions, negative symptoms and functional impairment despite adequate pharmacological treatment. Every additional failed medicine can increase frustration without meaningfully changing the disease.
That makes neuromodulation attractive. tDCS is non-invasive, relatively inexpensive and technically simpler than many other brain-stimulation approaches. In this trial, ten sessions delivered over five days produced a large short-term symptom difference relative to sham stimulation.
But large effects in small trials deserve more scrutiny, not less. Only 39 participants completed treatment, the intervention occurred in an inpatient setting, and investigators did not establish whether improvement persisted weeks or months later. Quality-of-life findings also failed to remain significant after statistical correction.
The responsible conclusion is therefore narrow and useful: fronto-temporal tDCS has produced a clinically interesting controlled signal in treatment-resistant schizophrenia.
The next trial now has to find out whether it is durable, reproducible and useful outside one hospital.
